Surgery Partners, Inc.

Surgery Partners, Inc. (SGRY) Market Cap

Surgery Partners, Inc. has a market capitalization of $1.91B.

Financials based on reported quarter end 2025-12-31

Price: $14.73

0.15 (1.03%)

Market Cap: 1.91B

NASDAQ · time unavailable

CEO: J. Eric Evans

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2015-09-30

Website: https://www.surgerypartners.com

Surgery Partners, Inc. (SGRY) - Company Information

Market Cap: 1.91B · Sector: Healthcare

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

Analyst Sentiment

71%
Strong Buy

Based on 22 ratings

Analyst 1Y Forecast: $20.16

Average target (based on 3 sources)

Consensus Price Target

Low

$15

Median

$19

High

$21

Average

$19

Potential Upside: 26.3%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 SURGERY PARTNERS INC (SGRY) — Investment Overview

🧩 Business Model Overview

Surgery Partners Inc (SGRY) operates as a leading provider of surgical services in the United States, specializing in short-stay surgical facilities and ancillary services. The company manages a diverse portfolio of ambulatory surgery centers (ASCs), surgical hospitals, and related ancillary businesses—including anesthesia, radiology, and laboratory services. Its decentralized, partnership-driven operating model empowers local facility management and leverages clinical autonomy to deliver efficient, high-quality care. Surgery Partners functions as a consolidator in the vast, fragmented US surgery center landscape, capitalizing on system-level trends favoring outpatient procedures over inpatient hospital care.

💰 Revenue Streams & Monetisation Model

Surgery Partners generates revenue primarily through facility fees for surgical procedures performed at its sites. These fees are paid by commercial health insurers, government payors (Medicare, Medicaid), and patients. Revenue varies by procedure category, payor mix, and geographic location, but is typically tied to procedure volume and case complexity. Ancillary revenue streams arise from value-added services such as anesthesia management, diagnostic imaging, pathology, and laboratory testing. The company monetizes its partnerships with physicians through equity stakes and management services agreements, which align incentives for volume growth and operational efficiency. Acquisition of additional facilities and organic ramp-up at existing sites both contribute to top-line expansion.

🧠 Competitive Advantages & Market Positioning

Surgery Partners is distinguished by its national scale, breadth of surgical specialties, and proven acquisition/integration capabilities. Its flexible partnership approach—offering shared ownership with entrepreneurial surgeons—has fostered strong relationships within the physician community, leading to high retention and procedure volume stability. The company benefits from favorable demographic trends (aging population, shift to minimally invasive techniques), as well as regulatory support for the migration of surgeries to outpatient settings. Unlike many health system operators, Surgery Partners is purpose-built to optimize ASC operations: its decentralized model allows for agile decision-making, customized local marketing, and clinical focus. This contrasts with less-nimble hospital systems, giving SGRY a cost and quality advantage in targeted procedures.

🚀 Multi-Year Growth Drivers

Multiple secular trends underwrite Surgery Partners’ long-term growth potential:
  • Procedure Migration: An expanding universe of surgical procedures is transitioning out of hospitals into ASCs, driven by advances in anesthesia, minimally invasive technology, and payer reimbursement reform.
  • Consolidation Opportunity: The ASC market remains highly fragmented, with a large share of centers independently owned. Surgery Partners has a substantial runway to grow through accretive acquisitions and by providing capital/operational expertise to physician partners.
  • Volume Growth from Demographics: The aging US population and prevalence of chronic conditions are expected to increase demand for surgical interventions, particularly orthopedic, cardiovascular, and pain management procedures.
  • Payer Incentives and Cost Savings: Shifting cases from inpatient to outpatient settings lowers total cost of care, incentivizing payers—both commercial and governmental—to favor ASCs. This trend aligns financial interests across patients, providers, and insurers.
  • Ancillary Services Expansion: Growth in higher-margin ancillary services, such as anesthesia and pathology, provides a means to capture greater value from each patient episode and enhances facility profitability.

⚠ Risk Factors to Monitor

Investors should be mindful of a variety of operational and macro-level risks:
  • Reimbursement Pressure: Changes to Medicare, Medicaid, or private payer reimbursement schedules can directly impact profit margins. Regulatory or contractual shifts may reduce procedure profitability.
  • Physician Relationships: Recruiting and retaining productive physician partners is essential to facility utilization. Competition for leading surgeons can be intense, and loss of key groups could depress volumes.
  • Integration and Execution: As an acquisitive consolidator, Surgery Partners faces ongoing challenges related to integration, cultural alignment, and achieving expected synergies from transactions.
  • Regulatory and Policy Risk: Healthcare services are subject to complex federal and state regulations, including licensing, anti-kickback, and corporate practice of medicine laws. Changes in policy or increased scrutiny could disrupt business operations.
  • Leverage and Capital Structure: Given its acquisition-driven model, Surgery Partners maintains a sizable debt load, making interest rates and access to capital markets important risk factors.

📊 Valuation & Market View

The market typically values Surgery Partners as both a healthcare growth platform and a unique consolidator within outpatient surgery. Valuation metrics, such as enterprise value to EBITDA (EV/EBITDA), often reflect a premium to general hospital operators, given SGRY’s higher revenue visibility, structural cost advantages, and faster expected growth profile. Further upside in valuation is closely linked to continued execution on both organic and M&A-driven expansion, as well as to the company’s ability to deliver steady margin improvement through operational leverage. Consensus views (as seen in typical sell-side coverage) favorably recognize Surgery Partners for participating in an enduring shift towards outpatient care and its strong physician alignment strategy. However, competitive bidding for new ASC assets, reimbursement uncertainty, and debt leverage are regularly cited as sources of valuation risk and potential volatility.

🔍 Investment Takeaway

Surgery Partners offers investors a compelling way to participate in transformative changes in the US healthcare delivery landscape. Its scale, physician-centric partnership model, and demonstrated acquisition prowess create a durable competitive position in the high-growth ambulatory surgery sector. While risk factors—such as payor-driven pricing dynamics and execution of a buy-and-build strategy—warrant close monitoring, the company’s structural tailwinds and robust runway for consolidation suggest multi-year opportunities for value creation. Overall, Surgery Partners stands out as a differentiated pure-play on the migration of surgical volume to more efficient, patient-preferred, and lower-cost ambulatory settings.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"SGRY reported revenues of $885M for the most recent period. However, the company is facing challenging times as it recorded a net loss of $15M and has negative earnings per share of $0.11. The balance sheet shows total assets of $8.24B against total liabilities of $4.72B, indicating a healthy equity position of $3.53B, though the net debt of $3.78B raises concerns regarding leverage. Cash flow remains a significant challenge, with zero operating cash flow and a free cash flow deficit of $12.8M. Shareholder returns have been unfavorable, with a 1-year price decline of 50.80%. This performance reflects not just in dividends—none were paid—but also in substantial capital depreciation. The current trading price of $12 is well below the consensus price target of $18.85, suggesting potential undervaluation, though the market performance reflects considerable skepticism. Overall, while SGRY shows potential in terms of asset holdings, profitability and shareholder returns need significant improvement to enhance investor confidence."

Revenue Growth

Fair

Stable revenue at $885M, but growth expectations are unclear.

Profitability

Neutral

Net loss of $15M and negative EPS indicate profitability challenges.

Cash Flow Quality

Neutral

Negative free cash flow of $12.8M raises concerns.

Leverage & Balance Sheet

Caution

Healthy equity position, but high net debt impacts leverage.

Shareholder Returns

Neutral

Significant decline of 50.80% in share price over the last year.

Analyst Sentiment & Valuation

Caution

Currently undervalued compared to price target, but sentiment is bearish.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management’s tone is candid but guarded: full-year results were $3.3B net revenue (low end) and $526M adjusted EBITDA that beat modestly YoY (+6.2% revenue, +3.5% EBITDA) while still missing expectations materially, with 15.9% adjusted EBITDA margin showing 40 bps compression. The key operational story is concentration—only three surgical hospital markets drove the Q4 shortfall—linked to a sharper payer mix shift and slower case growth, combined with a cost-structure lag (labor and anesthesia coverage) that didn’t adjust quickly enough. Management attributes payer pressure to physician transitions and slower physician ramp, plus near-term market-specific dynamics. The upside catalysts (orthopedics, robotics, physician recruitment, and de novo pipeline) remain intact, but the 2026 guidance resets (net revenue $3.3B–$3.45B; adjusted EBITDA ≥$530M, +0.7% growth) explicitly assume near-term headwinds persist. Notably, the transcript excerpt ends before Q&A, so we cannot measure analyst pressure or follow-up challenges on EPS/rev specifics.

AI IconGrowth Catalysts

  • Orthopedic/high-acuity shift: >42,000 orthopedic cases in Q4; total joints +15% in Q4 and +19% YTD
  • Robotics expansion: 74 surgical robots in service; +6 robots added during 2025
  • Physician recruitment: ~700 physicians recruited in 2025
  • De novo ASC development: opened 4 de novos in Q4; 8 total openings in 2025 (12–18 months to build; ~1 additional year to reach breakeven)

Business Development

  • Baylor Scott & White joint venture for surgical hospital in Bryan, Texas: facility will no longer be consolidated; expected run-rate earnings contribution improvement due to more efficient capital structure and improved physician alignment

AI IconFinancial Highlights

  • Full-year net revenue: $3.3B (low end of expectations), +6.2% YoY
  • Same-facility revenue growth: +4.9%
  • Full-year adjusted EBITDA: $526M (+3.5% YoY) but significantly below expectations
  • Adjusted EBITDA margin: 15.9% (40 bps margin compression YoY)
  • Q4 performance: fell short of revised expectations (no exact EPS/Rev surprise provided in transcript excerpt)
  • Margin pressure drivers concentrated in 3 surgical hospital markets: slower case growth + sharper payer mix shift, and labor/anesthesia cost structure not adjusting quickly enough

AI IconCapital Funding

  • 2025 capital deployment for acquisitions: $182M (below annual target of $200M plus divestiture proceeds; back-end weighted)
  • Portfolio optimization objective: reduce leverage and improve cash conversion as a % of adjusted EBITDA (specific buyback/debt/cash runway not provided in excerpt)

AI IconStrategy & Ops

  • Portfolio optimization: selectively partnering/divesting facilities outside core short-stay surgical strategy; negotiations in progress; expected to be value-accretive (reduced leverage/increased cash conversion)
  • New leadership focus: newly named Chief Operating Officer Justin Oppenheimer dedicating substantial time to support success at impacted facilities
  • 2026 planning approach: “measured and conservative” preliminary guidance resets for parts of the business

AI IconMarket Outlook

  • 2026 initial guidance (preliminary): net revenue $3.3B to $3.45B (single-digit YoY growth)
  • 2026 initial guidance: at least $530M adjusted EBITDA (implies +at least 0.7% growth), explicitly incorporating near-term impact from discussed headwinds
  • Management cited supplemental slide quantifying headwind impacts (not included in excerpt)

AI IconRisks & Headwinds

  • Second-half 2025 headwinds: delayed net capital deployment plus slower case growth and adverse payer mix trends (started in Q3 and continued into Q4)
  • Concentration risk: earnings shortfall concentrated in only three surgical hospital markets
  • Payer mix pressure: driven by physician transitions (retirements/departures) and newly recruited physicians serving a higher Medicare mix and not ramping as quickly
  • Cost lag risk: labor expenses and anesthesia coverage costs did not adjust quickly enough to the changing payer mix in impacted surgical hospital markets
  • Anesthesia dynamics specifically pressured in surgical hospitals with higher Medicare mix (less broad-based across ASC footprint)

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the SGRY Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (SGRY)

© 2026 Stock Market Info — Surgery Partners, Inc. (SGRY) Financial Profile